|
gptkbp:instanceOf
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Daiichi_Sankyo_Europe_GmbH
gptkb:Ranbaxy_Laboratories
gptkb:Daiichi_Sankyo_UK_Ltd.
|
|
gptkbp:CEO
|
gptkb:Seigo_Kikuchi
|
|
gptkbp:clinicalTrials
|
ongoing
collaborative studies
patient-centered trials
|
|
gptkbp:collaborations
|
gptkb:Harvard_University
gptkb:University_of_Tokyo
|
|
gptkbp:employees
|
approximately 15,000
|
|
gptkbp:founded
|
2005
|
|
gptkbp:founder
|
gptkb:Daiichi_Pharmaceutical
|
|
gptkbp:global_presence
|
over 20 countries
|
|
gptkbp:headquarters
|
gptkb:Tokyo,_Japan
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Daiichi Sankyo Company
|
|
gptkbp:innovation
|
gene therapy
biologics
small molecules
|
|
gptkbp:market
|
global pharmaceutical market
European_pharmaceutical_market
Japanese_pharmaceutical_market
North_American_pharmaceutical_market
|
|
gptkbp:partnerships
|
gptkb:GSK
gptkb:AstraZeneca
gptkb:Johnson_&_Johnson
gptkb:Takeda_Pharmaceutical_Company
gptkb:Boehringer_Ingelheim
gptkb:Bristol-Myers_Squibb
gptkb:Baxter_International
gptkb:Pfizer
gptkb:Merck_&_Co.
gptkb:Roche
gptkb:Amgen
gptkb:Eisai
gptkb:Sandoz
gptkb:Astellas_Pharma
Novartis
Sanofi
AbbVie
Celgene
|
|
gptkbp:philanthropy
|
education programs
healthcare_initiatives
|
|
gptkbp:products
|
antibiotics
vaccines
oncology drugs
|
|
gptkbp:research_focus
|
central nervous system disorders
cardiovascular diseases
metabolic diseases
|
|
gptkbp:revenue
|
$10 billion (2020)
|
|
gptkbp:stockExchange
|
gptkb:Tokyo_Stock_Exchange
|
|
gptkbp:stockSymbol
|
4568
|
|
gptkbp:subsidiary
|
gptkb:Daiichi_Sankyo,_Inc.
|
|
gptkbp:sustainability_initiatives
|
community engagement
ethical practices
environmental responsibility
|